Thermo Fisher opened a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, placing additional assay and analytical capacity inside GoCo Health Innovation City. The facility is intended to support pharma and biotech customers across drug development phases and is equipped for cell-based assays, immunochemistry, LC-MS, molecular genomics, flow cytometry, and proteomics. Thermo said the move complements existing bioanalytical labs in Richmond, Virginia, and Suzhou, China, indicating continued regional scaling of discovery and translational testing capabilities. For biotech teams, the expansion can translate into faster turnarounds and higher local throughput for biomarker-driven programs. Thermo also authorized a quarterly dividend, but the operational signal for the sector is the laboratory capacity buildout aimed at supporting biomarker-heavy clinical pipelines.